Approval of the first vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has dramatically changed the prospects of controlling coronavirus disease 2019 (COVID-19). According to the first available data, these vaccines appear effective and safe, but no clinical trials have included patients with rheumatic diseases, and no data exists on efficacy and safety in such subjects.
No takes yet. Share an insight, caveat, or question.
Conticini et al. (2021) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: